|
Aug 26
|
Actinogen Medical (ASX:ACW) shareholder returns have been enviable, earning 506% in 5 years
|
|
Aug 26
|
Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
|
|
Jun 26
|
Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
|
|
Nov 28
|
Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
|